AHSCT

AcronymDefinition
AHSCTAllogeneic Hematopoietic Stem-Cell Transplantation
AHSCTAutologous Hematopoietic Stem Cells Transplantation
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
In the period before 2000, the main indications for AHSCT were CML and AA.
The projected five-year survival rate in MDS patients after AHSCT is 34% if we exclude the patients with advanced, late disease.
NHS England said the AHSCT treatment is commissioned at specialised centres in the UK but is currently only offered to some people with MS.
Although we could not find a similar study on the late effects of AHSCT on the immune system, absolute lymphopenia, CD4 lymphopenia, CD8 lymphopenia, low Th/Ts ratio, and low Ig levels were the detected abnormalities with regard to the immune system in our study.
The findings show that older patients and those with the most severe forms of the disease have a higher risk of death, however, younger patients, who have failed to respond to other MS drugs and who have relapsing MS, could benefit from AHSCT.
This clinical trial is the expansion of the company's Phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.
Serum free light chain assays performed after AHSCT showed normal free [kappa] and [lambda] light chain levels until March 2009, when free [kappa] light chain levels first become elevated.
reported a patient with an adrenal EMP that had a partial response to initial AHSCT and complete remission after repeat AHSCT (6).
Radiation therapy and chemotherapy have been used in AHSCT. The frequent finding of drug resistance to any single agent in a cancer cell subpopulation generally mandates the use of multiple drugs, with or without radiation therapy.
Allogeneic hematopoietic stem cell transplantation (AHSCT) recipients are highly susceptible to viral infections because of immunosuppression related to conditioning regimens, T-cell depletion, and graft versus host disease (GVHD) (1).
Materials and Methods: We retrospectively analyzed 423 patients who underwent AHSCT. We assessed age, sex, pretransplant diagnosis, conditioning regimen, GVHD prophylaxis, and occurrence of acute GVHD (aGVHD), chronic lichenoid and chronic systemic GVHD, and clinical properties of sclerodermatous GVHD.
Overall survival (OS) in patients with the done AHSCT amounted to 55 months, whereas in the group of patients treated with chemotherapy protocols OS amounts to 24 months.